Innovating Works

CSC-IS

financed
Development of a more effective and safer therapeutic antibody for cancer treatm...
Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour s immune system. Global cancer market is growing at a CAGR of 6.9% with an estimated value of $81bn in 2016. Although the huge R&D investment observed in the past years in the development of new treatments, there is still lack on an effective trea... see more
31/12/2016
FUNDACIO PRIVADA I...
150K€
Project Budget: 150K€
see more

Project leader
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCO... No se ha especificado una descripción o un objeto social para esta compañía.
TRL 4-5 | 16M€
PARTICIPATION DEPralty Sin fecha límite de participación.
Financing granted El organismo H2020 notifico la concesión del proyecto The day 2016-12-31
ERC-PoC-2014: ERC Proof of Concept Grant Scope:Objectives
Cerrada does 11 years
0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.